When my grandmother passed away last year at 100 years old, I sat with the truth of her life and her legacy. Aside from being a wife, a passionate teacher, a mother of five, a grandmother of 22, and a great grandmother of 17. What really struck me was how she thrived.No chronic illnesses, no prescription pills, no confusion about what to eat. She ate from the land. She cooked from home.She trusted what she knew. Wisdom passed on from generations before her. Her quality of life got me thinking, when did some ...

Most startups fighting livestock emissions work from the outside in.Hoofprint Biome is doing the opposite and using enzymes to reprogram the cow gut itself. Hear the full story (and how they raised $15M) on @EquityPod 🐮Listen here: https://t.co/sMh6kMX5fK, or wherever you get your podcasts! ...

Core Viewpoint - Theriva Biologics is presenting interim blinded safety and pharmacokinetic data for SYN-004 at the ESCMID Global Congress, focusing on its potential to prevent acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients [1][3]. Group 1: Clinical Trial Details - The ongoing Phase 1b/2a clinical trial is randomized, double-blinded, and placebo-controlled, evaluating the safety and tolerability of oral SYN-004 in allogeneic HCT recipients receiving IV antibiotics [3]. - The trial is being conducted at Washington University School of Medicine and aims to enroll up to 36 participants across three cohorts, each receiving different IV beta-lactam antibiotics [3]. - Safety and pharmacokinetic data are reviewed by an independent Data and Safety Monitoring Committee to determine the progression to the next cohort [3]. Group 2: About SYN-004 - SYN-004 (ribaxamase) is designed to degrade certain IV beta-lactam antibiotics in the gastrointestinal tract, maintaining gut microbiome balance and preventing Clostridioides difficile infection and acute graft-versus-host disease [4][6]. - A previous Phase 2b clinical trial with 412 patients showed that SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis, leading to better maintenance and recovery of the microbiome [4]. Group 3: Company Overview - Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, with a subsidiary working on an oncolytic adenovirus platform [5][6]. - The company's lead candidates include VCN-01, SYN-004, and SYN-020, targeting various aspects of cancer treatment and microbiome protection [6].